Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Trump administration launches new immigration crackdowns in New Orleans and Minneapolis. Here are all the cities it has targeted so far. - 2Watch This Glacier Race into the Sea
- 3Vote in favor of your #1 sort of juice
- 4'Heated Rivalry' is just the tip of the iceberg. How hockey became the sexiest sport
- 5The risk of falling space junk hitting airplanes is on the rise, experts warn
- An Extended period of Voyaging Carefully: the World with Reason
- Vote In favor of Your Favored Web-based Venture Stage
- Step by step instructions to Safeguard Your Teeth During Sports Exercises
- Instructions to Comprehend and Use Open Record Extra Offers
- In vogue Sleepwear Patterns for 2024
- Figure out How to Augment the Advantages of a Web-based Degree
- Instructions to Pick the Right Dental Embed Trained professional: An Exhaustive Aide
- Sweet Taste? Candy Fulfills You
- Private sector revives the climate disaster database Trump tried to squash
